Repligen Co. (NASDAQ:RGEN) Shares Sold by Banque Pictet & Cie SA

Banque Pictet & Cie SA cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 8.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,392 shares of the biotechnology company’s stock after selling 2,061 shares during the period. Banque Pictet & Cie SA’s holdings in Repligen were worth $3,223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Champlain Investment Partners LLC lifted its stake in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after purchasing an additional 203,011 shares during the period. DF Dent & Co. Inc. boosted its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares during the period. Two Sigma Advisers LP boosted its stake in Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after purchasing an additional 102,100 shares during the period. Finally, Fred Alger Management LLC boosted its stake in Repligen by 29.5% in the 3rd quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after purchasing an additional 90,831 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Finally, HC Wainwright cut their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $186.00.

Repligen Stock Performance

Repligen stock opened at $146.92 on Friday. The firm’s fifty day simple moving average is $155.42 and its 200-day simple moving average is $149.16. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS. On average, equities research analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.